苏映雪
发布时间：2022-09-14 浏览：3143
苏映雪，副主任药师，药理学博士。一直专注于眼用制剂研发，作为技术骨干参与了多个新药的药学研究，其中包括治疗白内障化学1类新药ZOC2017217滴眼液的研制和开发，主要负责药学研究和新药临床试验申报，该药已获得国家1类新药临床试验批件，完成了I期和II期临床试验并获积极结果，已进入III期临床试验，实现白内障治疗的重大突破。主持国家自然科学青年基金、广东省医学科学技术研究基金、广东省中医药局科研基金，以第一作者/共同第一作者在 Gut、Cell Death Dis等杂志发表论文。
Yingxue Su, Associate Chief Pharmacists, Doctor of Pharmacology. She has been focused on the development of ophthalmic preparations. As a technical backbone, she has participated in multiple new drugs pharmaceutical research, including the first-in-class innovative cataract drug ZOC2017217 eye drops, and has been mainly responsible for pharmaceutical research and clinical trial application. ZOC2017217 eye drops has completed Phase I and Phase II clinical trials with positive results, entered Phase III clinical trials and achieved a major breakthrough in cataract treatment. She has undertaken NSFC Young Scientist Fund, Medical Scientific Research Foundation of Guangdong Province and published papers in Gut, Cell Death Dis and other journals.
返回列表
|
